

AMENDED IN SENATE APRIL 18, 2016

AMENDED IN SENATE APRIL 4, 2016

SENATE BILL

No. 1408

Introduced by Senator Allen

February 19, 2016

An act to amend Section 1644.5 of the Health and Safety Code, relating to public health.

LEGISLATIVE COUNSEL'S DIGEST

SB 1408, as amended, Allen. Tissue donation.

~~Existing~~

(1) *Existing* law prohibits the transfer of any tissues, as defined, into the body of another person by means of transplantation, unless the donor of the tissues has been screened and found nonreactive for evidence of infection with human immunodeficiency virus (HIV), agents of viral hepatitis (HBV and HCV), human T lymphotropic virus (HTLV), and syphilis, except as provided. Existing law requires that all donors of sperm be screened and found nonreactive under the above provisions, except as provided. Existing law authorizes the transplantation of tissue from a donor who has not been tested for specified infectious diseases or, with the exception of HIV and HTLV, has been found reactive, if specified conditions are satisfied.

This bill would delete the exception of HIV from this provision.

(2) *Under existing law, it is a felony for a person to donate blood, body organs or other tissue, or semen to a medical center or semen bank who knows that he or she has acquired immunodeficiency syndrome (AIDS) except if the person is a sperm donor who has been screened and found nonreactive under the above provisions. Under existing law, a person afflicted with any contagious, infectious, or*

communicable disease who willfully exposes himself or herself to another person, and any person who willfully exposes another person afflicted with the disease to someone else, is guilty of a misdemeanor, except as provided.

This bill would exempt those sperm donors and tissue donors from those criminal provisions.

Vote: majority. Appropriation: no. Fiscal committee: no.
State-mandated local program: no.

The people of the State of California do enact as follows:

1 SECTION 1. Section 1644.5 of the Health and Safety Code is
2 amended to read:

3 1644.5. (a) Except as provided in subdivision (c) or (d), no
4 tissues shall be transferred into the body of another person by
5 means of transplantation, unless the donor of the tissues has been
6 screened and found nonreactive by laboratory tests for evidence
7 of infection with human immunodeficiency virus (HIV), agents
8 of viral hepatitis (HBV and HCV), and syphilis. For tissues that
9 are rich in viable leukocytes, the tissue shall be tested for evidence
10 of infection with human T lymphotropic virus (HTLV) and found
11 nonreactive. The department may adopt regulations requiring
12 additional screening tests of donors of tissues when, in the opinion
13 of the department, the action is necessary for the protection of the
14 public, donors, or recipients.

15 (b) Notwithstanding subdivision (a), infectious disease screening
16 of blood and blood products shall be carried out solely in
17 accordance with Article 2 (commencing with Section 1602.5) of
18 Chapter 4.

19 (c) All donors of sperm shall be screened and found nonreactive
20 as required under subdivision (a), except in the following instances:

21 (1) A recipient of sperm, from a sperm donor known to the
22 recipient, may waive a second or other repeat testing of that donor
23 if the recipient is informed of the requirements for testing donors
24 under this section and signs a written waiver.

25 (2) A recipient of sperm may consent to therapeutic insemination
26 of sperm or use of sperm in other assisted reproductive technologies
27 even if the sperm donor is found reactive for hepatitis B, hepatitis
28 C, syphilis, HIV, or HTLV if the sperm donor is the spouse of,
29 partner of, or designated donor for that recipient. The physician

1 providing insemination or assisted reproductive technology services
2 shall advise the donor and recipient of the potential medical risks
3 associated with receiving sperm from a reactive donor. The donor
4 and the recipient shall sign a document affirming that each
5 comprehends the potential medical risks of using sperm from a
6 reactive donor for the proposed procedure and that each consents
7 to it. Copies of the document shall be placed in the medical records
8 of the donor and the recipient.

9 (3) (A) Sperm whose donor has tested reactive for syphilis may
10 be used for the purposes of insemination or assisted reproductive
11 technology only after the donor has been treated for syphilis. Sperm
12 whose donor has tested reactive for hepatitis B may be used for
13 the purposes of insemination or assisted reproductive technology
14 only after the recipient has been vaccinated against hepatitis B.

15 (B) (i) Sperm whose donor has tested reactive for HIV or HTLV
16 may be used for the purposes of insemination or assisted
17 reproductive technology for a recipient testing negative for HIV
18 or HTLV only after the donor's sperm has been effectively
19 processed to minimize the infectiousness of the sperm for that
20 specific donation and where informed and mutual consent has
21 occurred.

22 (ii) The department shall adopt regulations regulating facilities
23 that perform sperm processing, pursuant to this subparagraph, that
24 prescribe standards for the handling and storage of sperm samples
25 of carriers of HIV, HTLV, or any other virus as deemed appropriate
26 by the department. The department may propose to adopt, as initial
27 regulations, the recommendations made within the "Guidelines
28 for Reducing Risk of Viral Transmission During Fertility
29 Treatment" as published by the American Society for Reproductive
30 Medicine. Notice of the department's proposed adoption of the
31 regulations shall be posted on the department's Internet Web site
32 for at least 45 days. Public comment shall be accepted by the
33 department for at least 30 days after the conclusion of the 45-day
34 posting period. If a member of the public requests a public hearing
35 during the 30-day comment period, the hearing shall be held prior
36 to the adoption of the regulations. If no member of the public
37 requests a public hearing, the regulations shall be deemed adopted
38 at the conclusion of the 30-day comment period. Comments
39 received shall be considered prior to the adoption of the final initial
40 regulations. The department may modify any guidance published

1 by the American Society for Reproductive Medicine. Adoption of
2 initial regulations by the department pursuant to this subdivision
3 shall not be subject to the rulemaking requirements of Chapter 3.5
4 (commencing with Section 11340) of Part 1 of Division 3 of Title
5 2 of the Government Code and written responses to public
6 comments shall not be required. Updates to the regulations shall
7 be adopted pursuant to the same process. Until the department
8 adopts these regulations, facilities that perform sperm processing
9 pursuant to this section shall follow facility and sperm processing
10 guidelines for the reduction of viral transmission developed by the
11 American Society for Reproductive Medicine. Nothing in this
12 section shall prevent the department from monitoring and
13 inspecting facilities that process sperm to ensure adherence to the
14 regulations, or, until regulations are adopted, to the guidelines set
15 forth by the American Society for Reproductive Medicine.

16 (iii) Prior to insemination or other assisted reproductive
17 technology services, the physician providing the services shall
18 inform the recipient of sperm from a spouse, partner, or designated
19 donor who has tested reactive for HIV or HTLV of all of the
20 following:

21 (I) That sperm processing may not eliminate all of the risks of
22 HIV or HTLV transmission.

23 (II) That the sperm may be tested to determine whether or not
24 it is reactive for HIV or HTLV.

25 (III) That the recipient must provide documentation to the
26 physician providing insemination or assisted reproductive
27 technology services prior to treatment that she has established an
28 ongoing relationship with another physician to provide for her
29 medical care during and after completion of fertility services.

30 (IV) The recommendations made within the “Guidelines for
31 Reducing the Risk of Viral Transmission During Fertility
32 Treatment” published by the American Society for Reproductive
33 Medicine regarding followup testing for HIV and HTLV after use
34 of sperm from an HIV or HTLV reactive donor and have the
35 recommendations regarding followup testing be documented in
36 the recipient’s medical record.

37 (iv) The physician providing insemination or assisted
38 reproductive technology services shall also verify, and document
39 in the recipient’s medical record, that the donor of sperm who tests

1 reactive for HIV or HTLV is under the care of a physician
2 managing the HIV or HTLV.

3 (v) The physician providing insemination or assisted
4 reproductive technology services shall recommend to the physician
5 who will be providing ongoing care to the recipient recommended
6 followup testing for HIV and HTLV according to the “Guidelines
7 for Reducing the Risk of Viral Transmission During Fertility
8 Treatment” published by the American Society for Reproductive
9 Medicine, which shall be documented in the recipient’s medical
10 record.

11 (vi) If the recipient becomes HIV or HTLV positive, the
12 physician assuming ongoing care of the recipient shall treat or
13 provide information regarding referral to a physician who can
14 provide ongoing treatment of the HIV or HTLV.

15 (4) A recipient of sperm donated by a sexually intimate partner
16 of the recipient for reproductive use may waive a second or repeat
17 testing of that donor if the recipient is informed of the donor testing
18 requirements of this section and signs a written waiver. For
19 purposes of this paragraph, “sexually intimate partner of the
20 recipient” includes a known or designated donor to whose sperm
21 the recipient has previously been exposed in a nonmedical setting
22 in an attempt to conceive.

23 (d) Subdivision (a) shall not apply to the transplantation of tissue
24 from a donor who has not been tested or, with the exception of
25 HTLV, has been found reactive for the infectious diseases listed
26 in subdivision (a) or for which the department has, by regulation,
27 required additional screening tests, if both of the following
28 conditions are satisfied:

29 (1) The physician and surgeon performing the transplantation
30 has determined any one or more of the following:

31 (A) Without the transplantation the intended recipient will most
32 likely die during the period of time necessary to obtain other tissue
33 or to conduct the required tests.

34 (B) The intended recipient already is diagnosed with the
35 infectious disease for which the donor has tested positive.

36 (C) The symptoms from the infectious disease for which the
37 donor has tested positive will most likely not appear during the
38 intended recipient’s likely lifespan after transplantation with the
39 tissue or may be treated prophylactically if they do appear.

- 1 (2) Consent for the use of the tissue has been obtained from the
2 recipient, if possible, or if not possible, from a member of the
3 recipient’s family, or the recipient’s legal guardian. For purposes
4 of this section, “family” shall mean spouse, adult son or daughter,
5 either parent, adult brother or sister, or grandparent.
- 6 (e) The penalties of ~~Section~~ *prescribed in Sections 1621.5 shall*
7 *and 120290 do not apply to a sperm donor covered under*
8 *subdivision (e). (c) or a tissue donor covered under subdivision*
9 *(d).*
- 10 (f) Human breast milk from donors who test reactive for agents
11 of viral hepatitis (HBV and HCV), HTLV, HIV, or syphilis shall
12 not be used for deposit into a milk bank for human ingestion in
13 California.